RD 784/34991 – Simbec-Orion Skip to content

HELP CLINICAL RESEARCH TODAY

If you are a healthy male or female, aged between 18 and 55, then you may be eligible to participate in a research study investigating a potential new treatment for conditions such as epilepsy, spasticity, anxiety and other conditions of the central nervous system.

Maximum inconvenience payment up to £2460.

study information

Simbec-Orion Clinical Pharmacology will soon be running a study to investigate a potential new drug called ENX-102.

The main objectives of this study are as follows:

  • To determine the safety and tolerability (degree to which side effects of a drug can be tolerated) of ENX-102 when it is administered as a single dose at different dose strengths on one occasion.
  • To investigate the amount of ENX-102 in the blood after a single oral dose, how the amount of ENX-102 in the blood changes over time, and whether there are differences in the amount of ENX-102 in the blood when ENX-102 is given at different dose strengths.

ENX-102 is being developed for the treatment of epilepsy, spasticity (a muscle disorder where muscles stiffen and spasm), anxiety, and other conditions of the central nervous system (brain and spinal cord). Currently, there are many different treatment options available for the conditions of the central nervous system mentioned above; however, these treatments are not very effective for long-term management of these conditions and can cause a number of significant side effects. Therefore, there is a need to develop new treatments which could be more effective in long-term treatment and have less associated side effects.

The purpose of the study is to evaluate the safety and tolerability of ENX-102, and to measure the amount of ENX-102 in the blood after it is given as a single dose on one occasion. The study will consist of 6 planned groups of 8 participants: with participants in each group receiving a different dose strength. During the study, you will be required to stay at the Simbec-Orion clinical unit for a minimum period of 5 days (4 overnight stays). It is possible that, based on the information obtained from previous group(s), the treatment period may be extended by an additional 1 or 2 days which would increase the number of overnight stays to a maximum of 6 instead of 4. Therefore, if you are screening for participation in Groups 2-6, you should ensure that you are available to complete all visits up to Day 6 if this is required.

study timeline

*As described in the study information section above, the treatment period may be extended up to a maximum of an additional 2 days which would increase the number of overnight stays to 6 instead of 4.

APPLY NOW

Thank you for your interest in joining our panel of healthy volunteers, please register by completing the below form.

This form does not exist